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Theory-based development of an
implementation intervention to increase
HPV vaccination in pediatric primary care
practices
Jane M. Garbutt1,2*, Sherry Dodd2, Emily Walling2,3, Amanda A. Lee4, Katharine Kulka2 and Rebecca Lobb4
Abstract
Background: The national guideline for use of the vaccine targeting oncogenic strains of the human papillomavirus
(HPV) is an evidence-based practice that is poorly implemented in primary care. Recommendations include completion
of the vaccine series before the 13th birthday for girls and boys, giving the first dose at the 11- to 12-year-old check-up
visit, concurrent with other recommended vaccines. Interventions to increase implementation of this guideline have
had little impact, and opportunities to prevent cancer continue to be missed.
Methods: We used a theory-informed approach to develop a pragmatic intervention for use in primary care settings to
increase implementation of the HPV vaccine guideline recommendation. Using a concurrent mixed methods design in
10 primary care practices, we applied the Consolidated Framework for Implementation Research (CFIR) to systematically
investigate and characterize factors strongly influencing vaccine use. We then used the Behavior Change Wheel (BCW)
and the Theoretical Domains Framework (TDF) to analyze provider behavior and identify behaviors to target for change
and behavioral change strategies to include in the intervention.
Results: We identified facilitators and barriers to guideline use across the five CFIR domains: most distinguishing
factors related to provider characteristics, their perception of the intervention, and their process to deliver the
vaccine. Targeted behaviors were for the provider to recommend the HPV vaccine the same way and at the same
time as the other adolescent vaccines, to answer parents’ questions with confidence, and to implement a vaccine
delivery system. To this end, the intervention targeted improving provider’s capability (knowledge, communication
skills) and motivation (action planning, belief about consequences, social influences) regarding implementing guideline
recommendations, and increasing their opportunity to do so (vaccine delivery system). Behavior change strategies
included providing information and communication skill training with graded tasks and modeling, feedback of coverage
rates, goal setting, and social support. These strategies were combined in an implementation intervention to be
delivered using practice facilitation, educational outreach visits, and cyclical small tests of change.
Conclusions: Using CFIR, the BCW and the TDF facilitated the development of a pragmatic, multi-component
implementation intervention to increase use of the HPV vaccine in the primary care setting.
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Background
There is a critical need for theory-based implementa-
tion interventions to improve the use of evidence-based
practices in healthcare settings [1–4]. A conceptual
framework that describes interactions between individ-
uals, organizations, and the external environment can
guide a comprehensive assessment of the implementa-
tion problem and identify important variables to con-
sider when designing an implementation intervention.
Improving use of evidence-based practices requires
behavior change, and in order to design effective inter-
ventions and allow purposeful improvements when
interventions fail, it is necessary to understand these
behaviors in context [1–3, 5]. Models and theories of
behavior and behavior change can be used to determine
who and what needs to change and to identify behavior
change strategies.
Until recently, this reasoned approach to develop-
ment of implementation interventions was hindered by
a bewildering array of implementation frameworks and
psychological theories of behavior change. In the past
10 years, behavioral scientists have tried to simplify im-
plementation frameworks and psychological theory for
use by implementation researchers. Damschroder and
colleagues developed the Consolidated Framework for
Implementation Research (CFIR) to consolidate and
unify key constructs from 19 published implementation
theories [3]. The CFIR identifies five major domains of
organizational context that influence successful imple-
mentation: characteristics of the implementation inter-
vention, the inner setting (the context through which
implementation will proceed), the outer setting (the
context in which the organization resides), implemen-
ter’s characteristics, and the processes of implementa-
tion [3]. Michie and colleagues consolidated 33 theories
of behavior and behavior change in order to develop a
theoretical framework for understanding behavior
change among health professionals [5–7]. Using con-
sensus among experts, they identified a theoretical
framework with 14 theoretical domains (or key theoret-
ical constructs) covering the main factors influencing
provider’s clinical behaviors and behavior change (The-
oretical Domain Framework, TDF) [5, 6, 8]. These do-
mains have been linked to a simplified model of
behavior change, the COM-B model, using a “Behavior
Change Wheel” (BCW). The COM-B model character-
izes behavior change in terms of capability, opportunity,
and motivation (COM-B). The BCW illustrates the in-
terventions and behavior change functions that link the
TDF to the COM-B model [2, 5, 7].
The Center for Disease Control and Prevention
(CDC) national guideline for use of the human papillo-
mavirus (HPV) vaccine is an evidence-based practice
that is poorly implemented in pediatric practices [9,
10]. The HPV vaccine is an effective vaccine targeting
oncogenic HPV strains. It is predicted to prevent over
90% of cancer attributed to HPV including cervical
cancer and other genitourinary and oral cancers in
men and women [11]. Importantly, cancer prevention
requires vaccination prior to exposure to the sexually
transmitted virus. To achieve this goal, the CDC guide-
line recommends completing the HPV vaccine series
for girls and boys before their 13th birthday and giving
the first dose at their 11- to 12-year-old check-up visit
concurrent with other recommended vaccines [9, 12].
However, the vaccine is underused and opportunities
to prevent HPV-related cancers are being missed [13].
In 2016, 10 years after the vaccine was first introduced
in the U.S., only 49.5% of eligible females and 37.5% of
eligible males aged 13–17 years had completed the
vaccine series [11].
Theory-informed implementation interventions are
urgently needed to increase use of HPV vaccine as rec-
ommended in the CDC guideline. Missing from the
research is a comprehensive assessment of the imple-
mentation problem and theory-informed behavior
change implementation strategies. Systematic reviews
suggest that physician-level interventions such as
audit and feedback and reminders and patient-level
interventions such as education and reminder and
recall have had at best a modest effect (~ 5% increase)
[10, 14–16]. Provider-focused multi-component inter-
ventions were considered to be the most promising.
Studies showing larger effects have been criticized for
being methodologically lacking [10, 14–16]. Theory-
informed, multi-component interventions may be
more effective than prior interventions that failed to
address all relevant barriers, and pragmatic ap-
proaches may provide scalable approaches to increase
use of this important vaccine.
This paper describes the systematic process of apply-
ing theory to develop a pragmatic intervention to in-
crease use of HPV vaccine as recommended in the
CDC guidelines. We used a multi-step approach
(Fig. 1). First, we applied the CFIR [3] to systematically
identify barriers and facilitators to completing the vac-
cine series by age 13 and identify priority barriers and
facilitators in a broad sample of pediatric primary care
practices. Then, we used the BCW and the TDF [6, 7]
to identify targeted behaviors and select interventions
with the strongest potential to increase adherence to
vaccine guidelines while reducing barriers to imple-
mentation. This systematic attempt to develop an
intervention to implement clinical guidelines for pa-
tient care was within the context of the healthcare
team and practice setting [1]. We selected intervention
components and the modes for delivery by considering
what was feasible and acceptable to primary care
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providers working in independent offices. These com-
ponents were combined to form a cohesive interven-
tion for future evaluation.
Methods
The study was approved by the Washington University
Human Research Protection Office and was guided by
an Advisory Board of three pediatricians, one pediatric
nurse practitioner, and two parents. The Advisory Board
assisted in the interpretation of study findings and the
development of the intervention.
Study participants
We invited all members of the Washington University
Pediatric and Adolescent Ambulatory Research Consor-
tium (WU PAARC) to participate. WU PAARC is a
practice-based research network of 79 community pedia-
tricians and 6 pediatric nurse practitioners associated
with Washington University. The 16 providers from ten
practices who volunteered to participate comprised the
study sample. Each participant provided written consent
and received $50 for completion of the semi-structured
interview as a token of appreciation for their time.
Identification of barriers and facilitators for HPV vaccine
use
Guided by the CFIR, we used qualitative methods to iden-
tify barriers and facilitators to guideline-recommended
HPV vaccine use and quantitative methods to identify
vaccine coverage rates. We then integrated results from
the qualitative and quantitative methods to identify
theoretical factors that distinguished HPV coverage [17].
Collection and analysis of qualitative data
The provider interview guide addressed the main CFIR
constructs and included both general and specific
open-ended questions. The interviews were designed to
last about 30 min and were conducted at the practices
between January 27, 2016, and May 24, 2016, by the
principal investigator (JG) and co-investigator (EW).
All interviews were digitally recorded and transcribed
verbatim by trained transcriptionists. The transcripts
were organized using NVivo software, and each tran-
script was analyzed using consensual qualitative
research methods with multiple analysts from diverse
disciplines [18].
Collection and analysis of vaccination data
For each provider, we abstracted gender, date of birth,
date of vaccine, and type of vaccine (HPV, tetanus,
diphtheria, and pertussis, Tdap, and meningococcal,
MCV4) from the chart of eligible adolescents. These
included 11- to 15-year-old girls and boys who
attended at least one office visit from January 1, 2014,
to December 31, 2014. For each practice and provider,
we computed the overall coverage with HPV vaccine
as the percentage of girls and boys who completed the
vaccine series (requiring three doses in 2014) by their
13th birthday (a HEDIS measure for adolescent care).
Integrated analysis of qualitative and vaccine coverage
data
For each transcript, ratings were assigned that reflected
the valence (positive or negative influence) of each CFIR
construct on implementation of HPV vaccine according
to the CDC guideline. This was done using a consensus
process. We examined rating patterns within and across
providers in the lowest and highest tertile groups for
HPV vaccine coverage to identify barriers and facilitators
and constructs that distinguished between groups [18].
Using maximum variation sampling based on coverage
(i.e., quantitative findings) enabled us to highlight quali-
tative results that differed by coverage [18].
Development of the implementation intervention
We used the TDF and the BCW to guide selection of
the implementation interventions. The TDF is what
Sales et al. describes as a fully developed theory be-
cause it answers the following questions: Why do
people behave as they do? Given the way they behave,
what would motivate them to change behavior [1]?
The TDF posits that behavior change involves three
essential conditions: capability, opportunity, and mo-
tivation. We organized findings from the integrated
analysis by these three essential conditions and then
matched the distinguishing factors to the behavioral
antecedents, and interventions mapped to the respect-
ive condition in the TDF. We used the work by Michie
Fig. 1 Steps for theory-based development of implementation intervention
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et al. and by Powell et al. to help us to derive the
intervention strategies [19–21]. Finally, we combined
intervention components into a cohesive intervention
for future testing.
Results
Identification of barriers and facilitators for HPV vaccine
use
Study participants
Sixteen providers (15 pediatricians and one pediatric
nurse practitioner) participated in both the qualitative
and quantitative studies. Five were male, 11 were female,
13 were Caucasian, 2 were African American, and one
was Asian. The 16 providers were drawn from ten prac-
tices, nine of which had multiple providers (2–6 pro-
viders per practice). Eight practices used an electronic
medical record (EMR).
Interviews
A brief overview of the qualitative data analysis within
the CFIR framework is provided here.
All providers were aware of the CDC recommenda-
tions to complete the HPV vaccine series by age 13
and universally assumed responsibility for vaccine de-
livery. Providers typically recommended initiation and
completion of the HPV vaccine series during 11- to
12-year-old well visits; however, the strength of this
recommendation varied. Most providers felt that infor-
mation about vaccine benefits was needed to counter
the misinformation parents received from the media
and other sources. To meet this perceived need, pro-
viders routinely informed parents that HPV vaccine
prevents cancer and sometimes they mentioned the
prevention of warts. Providers varied in sharing per-
sonal information about vaccinating their children or
grandchildren. Some provided the information rou-
tinely while others only provided this information if
asked. All providers used the vaccine information
sheets (VIS) from the CDC to provide parental educa-
tion. Whenever parents wanted to know which of the
available vaccines at 11- to 12-year-old well visits were
mandatory for school attendance, providers routinely
recommended the HPV, Tdap, and MCV4 vaccines,
but suggested HPV vaccine was optional.
Delivery of HPV vaccine fit well with existing workflows
in practices that delivered Tdap and MCV4 to all adoles-
cents at the 11- to 12-year-old check-up visits, but
required an additional visit when vaccination was delayed.
Most providers were unaware of how their medical assist-
ant or nurse approached scheduling follow-up doses with
parents, and teamwork to deliver the vaccine series was
uncommon. All providers offered vaccine-only visits and
follow-up doses at acute care visits, and few practices rou-
tinely booked follow-up appointments or made reminder
calls to parents. Most often the responsibility to schedule
the second and third doses was left to the parent.
Commonly reported difficulties with providing HPV
vaccine included taking longer to discuss HPV vaccine
than other vaccines and dealing with the resistance
and hesitancy of parents. Many felt that they could
not persuade hesitant parents to provide HPV vaccine
for their child and some preferred to delay discussion
of prevention of a sexually transmitted cancer until
the child was older and the parent was more accept-
ing. Despite commonly experiencing challenges with
giving HPV vaccine, few providers reported efforts to
improve the system of vaccine delivery and none
monitored vaccine coverage.
Vaccine coverage
In 2014, across all study sites, 13.9% of 4592 eligible
teens had completed the HPV vaccine series before
their 13th birthday (16.9% girls, 11.3% boys). This
metric varied among practices from 2.3% to 25.5%. In
the five practices where more than one provider partici-
pated in the study, this metric varied four- to fivefold
among providers within the same practice. Due to this
intra-practice variation among providers, we chose to
analyze the integrated data at the level of the individual
provider rather than at the level of the practice.
Integrated analysis
We identified fourteen constructs that distinguished be-
tween providers with higher versus lower HPV vaccine
coverage that span the five domains of the CFIR. They
are summarized and characterized as facilitators and
barriers to guideline-recommended vaccine use in
Table 1.
Development of the implementation intervention
From the CFIR analyses, we found that most distin-
guishing factors between higher and lower coverage
related to provider characteristics—their lack of buy-in
to vaccination by age 13, their lack of confidence to
address parental hesitancy, and poor communication
skills to promote timely HPV vaccine use. Also, cover-
age was higher in practices with co-ordination between
the provider and staff to ensure opportunities for vac-
cination were not missed. We concluded that the
provider was the one whose behavior needed to change
to increase vaccine coverage, and identified three tar-
geted behaviors: (1) recommend getting the HPV
vaccine in the same way and at the same time as other
adolescent vaccines; (2) answer parent’s questions
about the vaccine with confidence; and (3) work with
staff and providers to develop a vaccine delivery system
using all possible resources.
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As illustrated in Table 2, behavior change strategies
were chosen to influence the determinants of the three
essential conditions of behavior changes from the BCW
(i.e., capability, opportunity, and motivation), address the
distinguishing barriers to implementation, and incorpor-
ate the distinguishing facilitators from Table 1. To in-
crease capability, the intervention is designed to improve
provider’s knowledge, communication skills, and self-
efficacy regarding implementing guideline recommenda-
tions. Audit and feedback of vaccine coverage data will
be used to increase motivation, and opportunity to in-
crease vaccine use will occur through development of an
integrated system for vaccine delivery within the prac-
tice. Strategies to change physician behavior will include
providing information, communication skill training
with graded tasks and modeling, action planning, goal
setting, and social support. These strategies have been
combined in an implementation intervention to be
delivered using educational outreach visits, use of
cyclical small tests of change, and practice facilita-
tion (Table 2). These approaches were chosen as
they have been shown to be effective in primary care
practices that lack resources needed to implement
change processes [22–24].
Tools
Educational materials for the provider include a commu-
nication strategy to help providers present information
in a more deliberate and impactful way to promote HPV
vaccination before the preteen becomes sexually active.
Educational materials for the parent were developed
as those currently available to provide information
about HPV vaccine were judged to be inadequate by
the Advisory Board. Specifically, our parent advisors
felt the CDC brochures contained too much informa-
tion and would not be read and providers wanted a
generic brochure that could be used for girls and boys.
Guided by the Advisory Board, we worked with the
Health Communication Research Laboratory at the
George Warren School of Social Work at Washington
University to develop posters and a brochure to provide
important information about HPV and HPV vaccine
and to promote vaccine use. We tested the acceptability
of these materials with a sample of 21 parents recruited
from study practices and revised them to include their
suggestions for improvement and address their
concerns.
Discussion
National recommendations for new vaccinations are not
usually packaged for easy implementation and primary
care providers continue to face considerable barriers
when trying to implement the adolescent immunization
schedule for HPV vaccine [25–28]. By using the CFIR to
systematically examine the complex web of factors that
influence the use of this important vaccine in the
Table 1 Summary of distinguishing factors for completion of HPV vaccine series by 13th birthday characterized using the CFIR(1)
CFIR domain Construct Effect
Intervention characteristics Relative advantage—at age 11–12 (increased immunogenicity, completion of series before risk,
access to at-risk population)
Facilitator
Adaptability—use older age of initiation Barrier
Outer setting Patient needs and resources—optional as not mandated by school Barrier
Peer pressure Barrier
External policy and incentives—financial incentives for series completion, e.g., meaningful use Facilitator
Inner setting Networks and communication—communication to coordinate implementation of 3 doses
across staff and providers
Facilitator
Readiness for implementation—leadership engagement in system level improvements and use
of available resources, e.g., EMR alerts, outreach calls
Facilitator
Characteristics of individuals Knowledge and beliefs—perceive value to completing by age 13 Facilitator
Knowledge and beliefs—perceive value to bundling Facilitator
Self-efficacy—confident to strongly recommend vaccine and to convince hesitant parents Facilitator
Self-efficacy—enthusiastic about HPV vaccine Facilitator
Readiness to change—has made personal efforts for improvement Facilitator
Process Planning—discuss/implement changes for increased vaccine use Facilitator
Engaging—involve staff in meaningful problem-solving Facilitator
Executing—strong recommendation, routinely provide at age 11/12, bundle 3 vaccines Facilitator
Reflecting and evaluating—with a view to making changes Facilitator
CFIR Consolidated Framework for Implementation Research
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primary care setting, we identified facilitators and bar-
riers to following national guidelines across all five do-
mains of the conceptual framework. Accepting
vaccination by age 13 was a critical aspect of providers’
ability and confidence to recommend the vaccine, ad-
dress parental hesitancy, and promote timely HPV vac-
cine use. Other opportunities for improvement included
better teamwork to share the work of vaccine delivery
and increase efficiency and ensure opportunities for vac-
cination were not missed.
Our findings informed a theory-based, multi-component
implementation strategy to change provider behavior
regarding vaccine use. Using the TDF, we identified behav-
ioral change targets and behavioral change approaches for
providers. The intervention includes audit and feedback of
vaccine coverage data to motivate providers to change
their approach to deliver HPV vaccine. Several features of
the audit and feedback component are considered “best
practices” [29]. These include using recent, individual-
level data, providing feedback in several different formats
(table, graph, oral), and repeating feedback cycles. At a
brief educational outreach visit, information about the
benefits of using the 11- to 12-year-old check-up visit to
initiate the vaccine series, both for the patient and for the
practice will be shared. The theory-based communication
plan provides key elements to guide practitioners’ conver-
sations about HPV vaccine and facilitate providing a
strong and persistent recommendation to complete the
vaccine series by age 13. As most independent primary
care practices lack the infrastructure and support for prac-
tice change, practice facilitation will be used to assist
providers to implement the change process and to engage
staff in the process [22]. Our hope is that this multi-
component intervention designed to address multiple
barriers will have a greater and more sustainable effect on
HPV vaccine use than prior interventions focused on one
or two barriers.
Several features of the proposed intervention are in-
novative and may inform implementing behavior
change in primary care practice. We developed a
Table 2 Selection of behavior change techniques and implementation change strategies to increase HPV vaccine use
COM-B factor
from the
BCW [2]
Potentially modifiable determinant
of behavior, i.e., barrier or facilitator
from CFIR-guided analysis [3]
Theoretical domain and techniques for
behavior change from TDF-guided
analysis [20]
Implementation strategy [19]
Capability Unaware of all benefits to the teen and
practice of vaccination at 11/12-year
check-up vs. deferring vaccine until older
(intervention characteristics, outer setting)
Knowledge
• Provide information about benefits of
HPV vaccine at 11/12-check-up for teen
and for practice
Develop and distribute educational
materials for provider
Conduct educational outreach visits
Capability Lack of ability to effectively recommend
HPV vaccine for use at the 11/12-year
check-up
(characteristics of individuals, outer setting,
and process)
Skills
• Model/demonstrate communication strategy
• Rehearse use of communication strategy
• Set goals for use of communication strategy
and monitor behavior
• Undertake graded tasks
Develop and distribute educational
materials
For providers: 4-part communication
strategy
• Make a strong recommendation
• Provide simple responses for common
questions
• Provide personal information about
vaccine use if appropriate
• Implement a follow-up plan if parent
is hesitant
For parents: brochures/posters
Test components of communication
strategy in cyclical small tests of change
using practice facilitation
Motivation No or limited interest in changing approach
to HPV vaccine delivery
(characteristics of individuals, inner setting)
Action planning
• Set goal for change
• Planning the change
Audit and provide feedback of HPV
vaccine coverage
Promote adaptability for target age to
encourage participation
Practice facilitation
Motivation Low self-confidence to provide strong
recommendation, address parental concerns
and deal with hesitant parents to allow
timely use of vaccine
(characteristics of individuals)
Belief about consequences
• Undertake graded tasks. Use problem-
solving, decision-making and goal setting
• Process for encouragement and support
• Provide feedback of improvement
Social influences
• Process for encouragement and support
Test components of communication
strategy in cyclical small tests of change
using practice facilitation
Tailor implementation strategies
Practice facilitation
Opportunity Lack of vaccine delivery system
(inner setting, process)
Environmental context and resources
• Environmental changes to process of HPV
vaccine delivery using all available resources
Conduct educational outreach visits
Reminders
Practice facilitation
Conduct cyclical small tests of change
BCW Behavior Change Wheel, CFIR Consolidated Framework for Implementation Research, TDF Theoretical Domain Framework
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simple, theory-based communication strategy that
builds on established behaviors used to recommend
other childhood vaccines. The implementation ap-
proach will allow providers to practice their communi-
cation about HPV vaccine, an effective strategy for
learning new skills [30]. Few studies have tried to im-
prove the quality of provider communication. Training
providers to use an announcement approach has been
shown to increase HPV vaccine coverage by 5% [31],
but the broader literature of message framing has
yielded mixed results [32]. Also, the intervention will
allow autonomy for providers to select the target age
for vaccine initiation with the goal to complete the
series by age 13 to 15. Autonomy is important for in-
trinsic motivation and may be important to engage pro-
viders in the change process [33]. Involving other staff
members in the system of care may be a pragmatic, al-
ternative approach to EMR-reminders [28] and other
strategies that may not be scalable without support.
Practice facilitation has been used successfully to im-
plement evidence-based interventions in primary care
practice that lack the resources to engage in the change
process [22].
Our study is limited in several respects. Our sample
consists of a small number of providers from one geo-
graphic area and may not be representative of other
populations. However, we believe the study sample is
representative of providers working in small-scale,
independently run community-based pediatric prac-
tices in our community with considerable variation in
the context of how the providers practiced. In this
setting, we were unable to examine the effect of deliv-
ery systems or practice leader engagement on vaccine
use. Completion of the three-dose series before the
13th birthday was low among participants but is con-
sistent with concurrent national data for this age group
[34]. The time span for collecting the quantitative and
qualitative data were different (2014 and 2016 respect-
ively). National data show the increase in HPV vaccine
coverage from 2014 to 2016 was minimal (about 5%)
[11, 34, 35], but if changes in coverage were not equal
across providers, then our assessment of barriers and
facilitators may be inaccurate.
Conclusions
In conclusion, study and national data suggest that wide-
spread efforts to increase HPV vaccine use are urgently
needed. We used the CFIR, the TDF, and BCW to sys-
tematically examine the use of this vaccine in independ-
ent primary care practices, identify targeted provider
behaviors for change, and guide our selection of behavior
change components needed to increase HPV vaccine use
according to guideline recommendations. This theory-
informed, multi-component implementation strategy
merits further investigation. After pilot testing to assess
feasibility, we are planning to seek funding to complete
a rigorous evaluation in a clinical trial in the primary
care setting to evaluate the effectiveness of this imple-
mentation strategy to make large improvements in
HPV vaccine use.
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